Phio Pharmaceuticals Corp. PHIOW 深 滬
等待開盤 08-15 09:30:00 美东时间
0.0232
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0232
- 總市值 10.63万
- 52周最高 1.16
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.006
- 委 比 0.00%
- 總股本 458.09万
- 歷史最高 1.16
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.006
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phio Pharmaceuticals Issues New Warrants for $2.5M
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an update. On July 25, 2025, Phi...
07-31 04:51
Phio Pharmaceuticals Announces New Manufacturing Agreement
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an announcement. On July 25, 202...
07-26 01:57
Phio Pharmaceuticals Reports Complete Tumor Clearance In cSCC Patient And Partial Response In Stage 4 Merkel Cell Carcinoma In Ongoing PH-762 Phase 1b Trial
Complete Pathologic Response in patient with cutaneous squamous cell carcinomaPartial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio
07-26 00:40
1. Phio Pharma CEO To Present New Skin Cancer Data On Groundbreaking Gene-Silencing Therapy PH-762
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today
06-24 19:47
HC Wainwright & Co. Assumes Phio Pharma at Buy, Announces Price Target of $14
HC Wainwright & Co. analyst Joseph Pantginis assumes Phio Pharma (NASDAQ:PHIO) with a Buy rating and announces Price Target of $14.
06-05 19:11
Phio Pharma To Present Update On Proprietary INTASYL Sirna Technology And Progress On On-Going Clinical Trial With Lead Compound PH-762 For Treatment Of Skin Cancers
Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA
05-19 19:50
Phio Pharma Q1 EPS $(0.47) Down From $(0.41) YoY
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.47) per share. This is a 14.63 percent decrease over losses of $(0.41) per share from the same period last year.
05-16 04:46
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results
The latest update is out from Phio Pharmaceuticals ( ($PHIO) ). On May 7, 2025,...
05-08 05:16
Phio Pharma Announces Pathology Results In Third Dose Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohortPhio to present trial results to date at a podium presentation at
05-07 19:47
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers icad (NASDAQ:ICAD) stock moved upwards by 73.0% to $3.34 during Wednes...
04-17 01:06
